首页 | 本学科首页   官方微博 | 高级检索  
     

美罗华联合Chop治疗弥漫大B细胞淋巴瘤对免疫功能及补体的影响
引用本文:别俊,李爽,李光明. 美罗华联合Chop治疗弥漫大B细胞淋巴瘤对免疫功能及补体的影响[J]. 西部医学, 2013, 0(12): 1780-1781,1784
作者姓名:别俊  李爽  李光明
作者单位:南充市中心医院肿瘤防治中心·川北医学院第二临床医学院,四川南充637000
基金项目:四川省卫生厅科研课题(120284)
摘    要:目的 探讨美罗华联合Chop方案治疗弥漫大B细胞淋巴瘤对机体免疫功能及补体的影响.方法 60例经病理证实的弥漫大B细胞淋巴瘤患者随机分为实验组和对照组,实验组(32例)采用美罗华联合Chop化疗,对照组(28例)单用Chop方案化疗.化疗前、后1、3、6、9、12月分别检测血清Ig及补体C3、C4值,并进行统计学分析.结果 实验组与对照组比较,实验组Ig水平及补体C3、C4均有下降,两组相比有统计学意义(P<0.05).结论 美罗华单抗联合Chop治疗弥漫大B细胞淋巴瘤对机体免疫功能及补体系统有一定影响,但尚需扩大样本量做进一步临床观察.

关 键 词:弥漫大B细胞淋巴瘤  美罗华  免疫球蛋白  补体

Rituximab combined with Chop for treatment of diffuse large B cell lymphoma and observation on immune function and complement
BIE Jun,LI Shuang,LI Guang-ming. Rituximab combined with Chop for treatment of diffuse large B cell lymphoma and observation on immune function and complement[J]. , 2013, 0(12): 1780-1781,1784
Authors:BIE Jun  LI Shuang  LI Guang-ming
Affiliation:(Nanchong Central Hospital, Nanchong 637000, Sichuan)
Abstract:Objective To observe the changes of immune and complement system during treatment of diffuse large B cell lymphoma by using rituximab combined with Chemotherapy. Methods 60 patients were divided into experimental and control groups. Experimental group was treated with rituximab and CHOP, and the control group was treated with CHOP. 1, 3, 6, 9 and 12 months after chemotherapy, the serum immunoglobulin and complement C3/C4 were detected. Results Compared with control group, the experimental group Ig levels and complement C3, C4 were decreased, and there was statistically significant. Conclusion I4n this study, rituximab combined with Chop treatment of diffuse large B cell lymphoma can effectively inhibit the immune function and the complement system ,But further clinical observation is needed.
Keywords:Follicular lymphoma  Rituximab  Immunoglobulin  Complement
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号